LOS ANGELES--(BUSINESS WIRE)--Lundin Law PC announces a class action lawsuit has been filed against TransEnterix, Inc. ("TransEnterix" or the "Company") (NYSE: TRXC) concerning possible violations of federal securities laws between February 10, 2016 and May 10, 2016 (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the August 1, 2016 lead plaintiff motion deadline.
No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
According to the complaint, the Company made false and/or misleading statements and/or failed to disclose that: there were deficiencies within the Company's 510(k) submission regarding the SurgiBot that undermined the likelihood that the SurgiBot would receive clearance from the Food and Drug Administration, which would leave TransEnterix unable to commercialize the SurgiBot in 2016, and would impair the Company's ability to obtain approval for and commercialize its other robotic surgery platform in the United States.
Lundin Law PC was created by Brian Lundin, a securities litigator based in Los Angeles.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.